Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Astena Holdings Co., Ltd. (8095.T)
Chuo, JP
Astena Holdings Co., Ltd., a Japanese company founded in 1914 and based in Chuo, is engaged in the development and distribution of a wide array of healthcare and chemical products. Its Fine Chemical division specializes in manufacturing and selling active pharmaceutical ingredients (APIs) and vital medical supplies used in treatments for fever reduction, pain relief, inflammation management, and blood vessel constriction. The Medical division focuses on biotechnology-related activities, providing support services for drug development and distributing essential medical equipment. The Health & Beauty Care, and Food segment is responsible for marketing non-prescription medications, raw materials for food and functional food products, and cosmetic ingredients. This division also manages direct-to-consumer sales through online and mail-order platforms, alongside offering contract manufacturing services for cosmetic items. Additionally, Astena Holdings' Industrial Chemicals division produces and supplies specialized chemicals for surface treatment and other industrial applications, serving sectors such as printed circuit boards, electronic devices, general plating processes, and semiconductors. The company, initially known as Iwaki & Co., Ltd., officially adopted the name Astena Holdings Co., Ltd. in June 2021.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.42% | -1.23% | +0.42% | -5.29% | +1.26% | -0.82% | +2.55% | +8.54% | -30.50% | +146.43% | +150.26% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+8.2% ★ Q2'26: +14.2% (vs Q2'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+185.8% ★ Q2'26: +5.9% (vs Q2'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+1.9% Q2'26: +2.8% (vs Q2'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+4.9% Q2'26: +6.3% (vs Q2'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+5.9% Q2'26: +8.8% (vs Q2'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.9% Q2'26: +0.2% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×4.11× Q2'26: 2.66× (vs Q2'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Nov 2019 actual |
Nov 2020 actual |
Nov 2021 actual |
Nov 2022 actual |
|---|---|---|---|---|
| Revenue |
61.65B
est: 63.30B (-2.6%)
|
65.34B
est: 64.00B (+2.1%)
|
72.32B
est: 73.00B (-0.9%)
|
49.64B
est: 78.00B (-36.4%)
|
| EBITDA |
3.17B
est: 3.94B (-19.5%)
|
4.27B
est: 3.98B (+7.3%)
|
5.21B
est: 4.54B (+14.8%)
|
3.90B
est: 4.85B (-19.6%)
|
| EBIT |
2.33B
est: 1.54B (+51.6%)
|
2.74B
est: 1.56B (+76.1%)
|
3.14B
est: 1.77B (+77.1%)
|
1.48B
est: 1.90B (-21.9%)
|
| Net Income |
1.53B
est: 2.01B (-23.9%)
|
1.98B
est: 2.18B (-9.1%)
|
1.74B
est: 2.69B (-35.4%)
|
579.60M
est: 3.04B (-80.9%)
|
| SGA |
2.89B
est: 3.20B (-9.6%)
|
2.58B
est: 3.23B (-20.0%)
|
2.65B
est: 3.68B (-28.2%)
|
2.91B
est: 3.94B (-26.1%)
|
| EPS |
47.01
est: 50.40 (-6.7%)
|
60.33
est: 54.60 (+10.5%)
|
46.86
est: 67.30 (-30.4%)
|
14.56
est: 76.10 (-80.9%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-25 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-01 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree International Equity Fund DWM | 0.01% | 90.5K | 0.48% |
| 2 | Dimensional - International Small Cap Value ETF DISV | 0.01% | 411.8K | 0.42% |
| 3 | Dimensional - International Small Cap ETF DFIS | 0.00% | 230.1K | 0.39% |
| 4 | Amundi Japan TOPIX II UCITS ETF EUR Dist JPNU.L | 0.00% | 25.8K | 0.45% |
| 5 | Avantis International Small Cap Equity ETF AVDS | 0.00% | 7.8K | 0.30% |
| 6 | iShares Core TOPIX ETF 1475.T | 0.00% | 303.0K | 0.05% |
| 7 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 167.4K | 0.22% |
| 8 | Dimensional International Sustainability Core 1 ETF DFSI | 0.00% | 11.1K | 0.24% |
| 9 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 97.8K | 0.28% |
| 10 | Dimensional - International Vector Equity ETF DXIV | 0.00% | 960.19 | 0.53% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Makoto Fujiwara | Managing Executive Officer | — | — |
| Masaaki Atami | Chief Financial Officer | — | — |
| Minoru Kadokura | Managing Executive Officer In charge of HBC/food business | — | male |
| Satoshi Setoguchi | President & Representative Director | — | male |
| Shinji Omori | Chief Human Resource Officer | — | — |
| Utano Shimizu | Managing Executive Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 8095.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
